glp 1 and 2 agonist Trends in the Development of GLP-1 Receptor Agonists Clinical Focus on GLP-1 Agonists
Description
doi:10.7150/ijbs.59965 This issue Cite Review 1
Competition Analysis: The GLP-1 Receptor Agonist market is characterized by a fragmented structure, with several players competing across various segments and regions
Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists
These so-called gliptins increase the incretin levels and therefore prolong the post-prandial insulin action
The duration of follow-up/intervention ranged from 3 months to 24 months across studies
